Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pidnarulex in Advanced Solid Tumors
NCT06606990Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pidnarulex in solid tumor, sponsored by National Cancer Institute. Primary endpoint: RAD51 response up to 3 years. Started Jul 2025; status: recruiting.
02
Drugs
pidnarulex
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06606990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06606990.